Welcome to our dedicated page for Sanara Medtech news (Ticker: SMTI), a resource for investors and traders seeking the latest updates and insights on Sanara Medtech stock.
Sanara MedTech Inc (SMTI) specializes in advanced collagen-based solutions for surgical and chronic wound care, serving healthcare providers through clinically validated technologies. This hub provides investors and medical professionals with centralized access to official corporate developments.
Key Resources: Track FDA clearances for medical devices, quarterly earnings reports detailing commercialization progress, and strategic partnership announcements with healthcare distributors. All content is sourced directly from company filings and verified press releases.
Content Types Include: Product launch details for wound care innovations, financial performance updates, clinical study outcomes, and executive leadership changes. Materials are organized chronologically for historical analysis and trend identification.
Staying Informed: Bookmark this page or check regularly for unedited primary source materials about SMTI's market position in medical technology. Cross-reference with regulatory databases for complete context on product approvals.
Sanara MedTech (Nasdaq: SMTI) and Biomimetic Innovations provided a progress update on OsStic™, a synthetic injectable structural bio-adhesive targeted for U.S. commercial launch in Q1 2027, conditional on anticipated FDA clearance. OsStic received FDA Breakthrough Device Designation (Dec 2023) and a U.S. patent was granted in 2025 (U.S. Patent No. 12,251,490) covering compositions, adhesives, kits, and prefilled syringes. The release cites preclinical mechanical testing showing 40x stronger bonding versus traditional calcium phosphate bone cement and notes ongoing product development, clinical, regulatory, and medical education milestones in 2025.
Sanara MedTech (Nasdaq: SMTI) said company management will present at the Piper Sandler 37th Annual Healthcare Conference in New York, running December 2–4, 2025. Management will deliver a presentation to investors on Wednesday, December 3 at ~9:30 a.m. Eastern Time. Presentation materials will be posted to the company’s investor relations website prior to the talk. A live audio webcast will be accessible under the Events section of the investor relations site, and an archive will be available for replay after the conference.
Sanara MedTech (Nasdaq: SMTI) reported third quarter 2025 results: Q3 net revenue $26.3M (+22% YoY) and YTD net revenue $75.6M (+25% YoY). Q3 adjusted EBITDA was $4.9M versus $2.6M a year ago; YTD adjusted EBITDA was $12.3M versus $5.1M. Net income from continuing operations was $0.8M in Q3 and $0.7M YTD. Gross margin improved to 93% in Q3. The company classified Tissue Health Plus (THP) as discontinued operations and recorded a $26.5M noncash impairment, contributing to Q3 discontinued losses of $31.2M and YTD discontinued losses of $36.7M. Cash was $14.9M and long-term debt $45.1M as of September 30, 2025.
Sanara MedTech (Nasdaq: SMTI) completed its evaluation of strategic alternatives for the Tissue Health Plus (THP) segment and has initiated a strategic realignment to discontinue THP operations and focus on its core surgical business.
The company ceased THP development in late September, will classify THP as discontinued operations under US GAAP, expects the wind‑down to continue through end of 2025, and projects $5.5M–$6.5M total cash investment in THP in the second half of 2025, with no material THP cash expenses expected after year‑end.
Sanara MedTech (Nasdaq: SMTI), a medical technology company specializing in surgical, chronic wound, and skin markets, has scheduled its Q3 2025 financial results announcement for November 12, 2025, before U.S. markets open.
The company will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day, featuring a Q&A session. Investors can access the call via toll-free number 888-506-0062 (international: 973-528-0011) using access code 874713. A replay will be available through November 26, 2025, and the webcast will be accessible for approximately one year on the company's investor relations website.
Sanara MedTech (NASDAQ: SMTI) announced a significant leadership transition, appointing Seth Yon as President, CEO, and Board Director, effective September 15, 2025. Yon, currently serving as President and Chief Commercial Officer, will succeed Ron Nixon, who will continue as Executive Chairman.
Under Yon's various leadership roles since joining in 2018, Sanara achieved remarkable 53% compound annual net revenue growth over the past three fiscal years. His progression through the company included positions as Director of Sales, National Sales Director, VP of Commercial, and President of Commercial.
The appointment represents the culmination of a strategic initiative to strengthen senior leadership and position Sanara for future growth in surgical, chronic wound, and skin markets. Yon brings 27 years of industry experience, including previous roles at Iroquois Industrial Group, GreenerGrads, and Jostens, Inc.
Sanara MedTech (NASDAQ: SMTI), a medical technology company specializing in surgical, chronic wound, and skin markets, will participate in the Cantor Global Healthcare Conference at the New York Marriott Marquis from September 2-5, 2025.
Management will conduct a fireside chat presentation on September 3, 2025, at 2:45 p.m. ET. Presentation materials will be available on the company's investor relations website before the event, and a live audio webcast will be accessible in the "Events" section, with replay available post-conference.
Sanara MedTech (Nasdaq: SMTI) reported strong Q2 2025 financial results with net revenue increasing 28% to $25.8 million year-over-year. The company's Sanara Surgical segment showed significant improvement, generating $0.5 million in net income and $4.7 million in Segment Adjusted EBITDA for Q2 2025.
Key highlights include gross margin improvement to 93% and operating loss reduction to just $31,000 compared to $2.9 million in Q2 2024. The company announced plans to evaluate strategic alternatives for its Tissue Health Plus (THP) subsidiary, which reported a net loss of $2.5 million in Q2 2025. As of June 30, 2025, Sanara had $17.0 million in cash and $44.2 million in long-term debt.
Sanara MedTech (NASDAQ: SMTI), a medical technology company specializing in surgical, chronic wound, and skin markets, has scheduled its second quarter 2025 financial results announcement for August 13, 2025, before U.S. markets open.
The company will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day to discuss Q2 2025 results and conduct a Q&A session. Investors can access the call via toll-free number 888-506-0062 (access code: 132343) or through the company's website.
Sanara MedTech (Nasdaq: SMTI) has launched a pilot program through its subsidiary Tissue Health Plus (THP) for value-based wound care services. The program partners with a wound care provider group operating across six states to deliver at-home chronic wound care.
The THP technology platform will serve as the provider group's Wound Care Operating System, featuring the Co-Pilot software for standardizing patient encounters and treatment interventions. The platform includes two-way EMR integration to streamline administrative processes. The company aims to launch another pilot program with a payer in the second half of 2025.
FAQ
What is the current stock price of Sanara Medtech (SMTI)?
What is the market cap of Sanara Medtech (SMTI)?
